What is Perimenopause?
Perimenopause is the transitional phase leading up to a woman’s final menstrual period — and for millions of American women, it is one of the most misunderstood chapters of their health journey. According to the National Institutes of Health (NIH) / NICHD, this transition typically begins between a woman’s mid-to-late 40s, though symptoms can surface as early as the mid-30s in some cases. During perimenopause, the ovaries gradually produce less estrogen and progesterone, triggering a cascade of hormonal fluctuations that can affect virtually every system in the body — from sleep and mood to bone density and cardiovascular health. The average age of menopause in the United States is 51–52 years, confirmed by both the Office on Women’s Health (OWH) and NIH StatPearls (updated March 2026), meaning perimenopause can last anywhere from 4 to 10 years before a woman reaches that final milestone.
What makes perimenopause in the US in 2026 particularly significant is the sheer scale of women experiencing it simultaneously. Every single day, approximately 6,000 women in the United States officially reach menopause — translating to roughly 1.3 million women annually entering this transition (Society for Women’s Health Research, SWHR). With the baby boomer generation continuing to age and life expectancy rising steadily, the US now has tens of millions of women navigating this phase at any given time. Yet awareness, healthcare access, and employer support remain deeply inadequate. A January 2026 global study by Flo Health and Mayo Clinic found that American women are significantly less informed about perimenopause than their counterparts in comparable nations — a gap that has direct consequences for delayed diagnoses, untreated symptoms, and lost economic productivity worth tens of billions of dollars annually.
Interesting Facts About Perimenopause 2026
PERIMENOPAUSE FAST FACTS — US 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
6,000 women/day ████████████████████ reach menopause daily (US)
1.3M women/year ████████████████████ enter menopause annually (US)
~51–52 yrs ████████████████ avg menopause age (US)
4–10 years ███████████ avg perimenopause duration
~90% ████████████████████ women with ≥1 moderate/severe symptom
80% ████████████████████ women experience hot flashes
85% ████████████████████ women feel uninformed about perimenopause
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Interesting Fact | Detail / Data | Source |
|---|---|---|
| Daily US menopause milestone | Approximately 6,000 women reach menopause every single day in the US | Society for Women’s Health Research (SWHR) |
| Annual transition volume | Roughly 1.3 million US women enter menopause each year | NIH StatPearls, March 2026 |
| Average menopause age in US | 51–52 years nationally, with wide variation by race/ethnicity | OWH / NICHD / NIH StatPearls |
| Perimenopause can start in the 30s | Symptoms can begin up to 10 years before the final menstrual period | Flo Health & Mayo Clinic Global Study, January 2026 |
| Typical perimenopause duration | Lasts an average of 6 years, but can extend up to 14 years | SWHR Menopause Disparities Fact Sheet |
| 1 in 100 women experience premature menopause | ~1% of US women reach menopause before age 40 | NIH / Grand View Research, 2024–2025 |
| Hot flashes are near-universal | About 80% of menopausal women experience hot flashes in the US | FDA, confirmed by NPR/FDA panel July 2025 |
| Most women feel uninformed | 85% of US women did not feel informed or knowledgeable about perimenopause | Biote Survey, 2024 |
| FDA updated MHT labeling Nov 2025 | FDA recommended removal of the boxed warning for estrogen replacement therapy in November 2025 | FDA Drug Alerts & Statements, 2025 |
| New non-hormonal drug approved 2025 | FDA approved elinzanetant (Lynkuet) on October 24, 2025 for vasomotor symptoms | Contemporary OB/GYN, January 2026 |
| By 2060, 90 million postmenopausal women | Projected 90 million US women will be postmenopausal by 2060 | Impacts of Menopause / Bayer FPA, July 2025 |
| Mental health diagnoses spike at perimenopause onset | Over 50% of US working women received a mental health diagnosis after perimenopause onset | Biote Survey, 2024 |
Source: NIH NICHD, Office on Women’s Health (OWH), Society for Women’s Health Research (SWHR), FDA Drug Alerts 2025, Flo Health & Mayo Clinic Global Digital Study January 2026, Biote Survey 2024
The table above paints a striking picture of just how widespread — and yet how underserved — perimenopause in America truly is. The sheer fact that 6,000 US women hit the menopause milestone every single day, combined with a transition period that can quietly begin a full decade earlier, means that at any given moment, tens of millions of women across every age bracket from their late 30s onward are living through some stage of the perimenopausal journey. The 85% awareness gap is particularly alarming: the vast majority of US women arrive at this crossroads completely unprepared, with no framework for understanding why their bodies, sleep, moods, and cognition are shifting.
The 2025–2026 regulatory milestones are genuinely historic. The FDA’s November 2025 decision to recommend removal of the long-standing boxed warning on menopausal hormone therapy — combined with the October 2025 approval of elinzanetant (Lynkuet) as a non-hormonal option — signals a turning point in how American medicine is beginning to take perimenopause treatment more seriously. The projection of 90 million postmenopausal women by 2060 is not a distant statistic; it is a policy emergency demanding systemic change in education, healthcare training, and workplace support structures today.
Perimenopause Symptoms in the US 2026 | Prevalence by Symptom Type
SYMPTOM PREVALENCE AMONG US PERIMENOPAUSAL WOMEN — 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Hot Flashes / Night Sweats ████████████████████ 75–82%
Sleep Disturbances ███████████████████ ~75%
Brain Fog / Cognitive Issues ███████████████ 60–65%
Mood Swings / Irritability ██████████████ 55–60%
Low Libido / Sexual Problems ████████████ 50–60%
Vaginal Dryness ████████████ 45–50%
Depression (perimenopausal) █████████ ~39%
Anxiety (diagnosed) ████████ ~33%
Irregular Periods ████████████████████ ~90% (hallmark symptom)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Perimenopause Symptom | Prevalence Among US Women | Key Detail |
|---|---|---|
| Irregular menstrual periods | ~90% of perimenopausal women | First and most defining symptom per NICHD |
| Hot flashes / vasomotor symptoms (VMS) | 75–82% of women during transition | SWAN Study data, NIH StatPearls 2026 |
| Night sweats | Included in VMS; affects 50–82% | SWAN Study / OWH |
| Sleep disturbances / insomnia | Approximately 75% of perimenopausal women | NIH / OWH menopause treatment page |
| Brain fog / cognitive difficulties | 60–65% experience memory lapses, concentration issues | NIH / OWH / Society for Women’s Health Research |
| Mood swings, irritability | 55–60% of perimenopausal women | NIH StatPearls; NCBI/NIH data |
| Low libido / sexual problems | 50–60% of women | NCBI/NIH; OWH |
| Vaginal dryness / VVA | 45–50% of postmenopausal women | NIH StatPearls, March 2026 |
| Depression (new or worsened) | 39% of women during/after menopause; 40% higher risk vs. premenopausal | NCBI/NIH StatPearls; Biote/NIH data |
| Anxiety (diagnosed) | 33% of women diagnosed and treated at perimenopause onset | Biote Survey, 2024 |
| Panic attacks | 13% diagnosed and treated at onset | Biote Survey, 2024 |
| Mood disorder diagnosis | 25% diagnosed and treated for mood swings | Biote Survey, 2024 |
Source: NIH NICHD, NIH StatPearls (updated March 2026), Office on Women’s Health (OWH), SWAN Study (NIH-funded), Biote Survey 2024
Perimenopause symptoms in the US in 2026 span a far wider clinical spectrum than most women — or even their physicians — anticipate. Hot flashes and vasomotor symptoms, affecting between 75% and 82% of US women according to the NIH-funded SWAN Study, remain the most widely recognized hallmark of the transition. But the data makes clear that the symptom burden extends well beyond the physical. The fact that 60–65% of perimenopausal women experience brain fog and cognitive issues — and that perimenopausal women carry a 40% higher risk for depressive symptoms compared to their premenopausal counterparts — underscores that the neurological and psychological dimensions of this transition demand far more clinical attention than they currently receive.
What is especially telling is the mental health data from the 2024 Biote Survey of over 1,005 US working women aged 30–60: more than half received a mental health diagnosis after perimenopause onset, with 33% diagnosed with anxiety and 27% with depression — conditions that were in many cases directly tied to hormonal shifts rather than pre-existing psychiatric illness. For millions of American women, these diagnoses came without any accompanying explanation linking their mental health changes to their hormonal transition, leaving them on psychiatric medications when the root cause was perimenopausal. This represents a profound failure in clinical education and diagnostic practice in the United States.
Perimenopause Treatment Options in the US 2026 | Hormonal & Non-Hormonal
US PERIMENOPAUSE TREATMENT LANDSCAPE — 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
MHT (Hormone Therapy) ████████████████████ Most effective for VMS
Fezolinetant (Veozah, 2023) ████████████████ FDA-approved non-hormonal
Elinzanetant (Lynkuet, 2025) ████████████████ FDA-approved Oct 24, 2025
SSRIs (Fluoxetine) █████████████ FDA-approved for hot flashes
Ospemifene ██████████ Approved for vaginal dryness
Lifestyle Modifications ████████████ Recommended by NIH/OWH
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Treatment Type | FDA Status / Recommendation | Treats | Key 2025–2026 Update |
|---|---|---|---|
| Menopausal Hormone Therapy (MHT / HRT) | FDA-approved; boxed warning removed November 2025 | Hot flashes, VVA, bone loss, sleep, mood | Labeling updated to remove cardiovascular/breast cancer warnings; endometrial cancer warning retained for estrogen-only |
| Fezolinetant (Veozah) | FDA-approved 2023 | Moderate-to-severe hot flashes (non-hormonal) | NK3 receptor antagonist; FDA liver injury warning issued — consult provider |
| Elinzanetant (Lynkuet) | FDA-approved October 24, 2025 | Moderate-to-severe hot flashes | Newest NK receptor antagonist; reshaping VMS treatment landscape per UVA Health experts |
| Fluoxetine (low-dose SSRI) | FDA-approved for hot flashes | Hot flashes (for women without existing mood issues) | Per OWH; not for women already on mood/anxiety treatment |
| Ospemifene | FDA-approved | Vaginal dryness, painful sex | Acts like estrogen locally; recommended by OWH |
| Lifestyle modifications | NIH/OWH recommended | All symptoms | Limiting alcohol/caffeine, healthy weight, exercise — NIH tips confirmed current |
| Federal guidance on MHT timing | Active (NIH/FDA 2025) | Systemic symptoms | Start within 10 years of menopause onset or before age 60 |
| Women NOT prescribed MHT who qualify | Substantial proportion (FDA, July 2025 Expert Panel) | — | FDA expressed concern that fear from boxed warnings left many undertreated |
Source: FDA Drug Alerts & Statements (November 2025), Office on Women’s Health — Menopause Treatment Page (updated 2026), NIH StatPearls (March 2026), Contemporary OB/GYN (January 2026)
The perimenopause treatment landscape in the US in 2026 is undergoing its most significant transformation in over two decades. The November 2025 FDA recommendation to remove the boxed warning on menopausal hormone therapy (MHT) is a watershed moment — one that followed a July 2025 Expert Panel convened specifically to reassess the risks and benefits of MHT in light of new evidence, updated patient demographics, and modern formulations. For years, that boxed warning — a legacy of the controversial 2002 Women’s Health Initiative (WHI) study — had led to a dramatic under-prescribing of MHT, leaving millions of eligible US women to suffer through preventable symptoms. The 2025 labeling revision maintains only the warning for endometrial cancer in estrogen-only products while removing references to cardiovascular disease, breast cancer, and probable dementia.
On the non-hormonal front, 2025 marked a turning point as well. The FDA approval of elinzanetant (Lynkuet) on October 24, 2025 gave clinicians a second neurokinin receptor antagonist option alongside fezolinetant (Veozah, approved 2023). Both medications work by targeting the hypothalamic neural pathways responsible for thermoregulatory instability during the perimenopausal transition — offering genuine clinical alternatives for women who cannot or prefer not to use hormones. Current federal guidance from NIH and FDA recommends initiating systemic hormone therapy within 10 years of menopause onset or before age 60, with duration and specific protocols determined collaboratively between patient and clinician. The OWH Menopause Treatment page (updated 2026) explicitly lists MHT, fezolinetant, fluoxetine, and ospemifene as FDA-approved tools — a reflection of an expanding, evidence-based pharmacological toolkit.
Perimenopause Healthcare Access & Awareness in the US 2026
HEALTHCARE ACCESS GAPS — US PERIMENOPAUSAL WOMEN 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
OB/GYNs untrained in menopause mgmt ████████████████████ ~80%
OB/GYN programs with menopause curric ██████ 31%
Perimenopausal women discussed w/ HCP ██████████ 49%
Women waiting 6+ months before care ████████████████████ ~50%
Women comfortable discussing at work ██████ 31%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Healthcare Access Metric | Statistic | Source |
|---|---|---|
| OB/GYN residency programs with menopause curriculum | Only 31% offer any formal menopause training | National Library of Medicine (NCBI/NIH) |
| OB/GYNs who report being untrained in menopause management | Estimated ~80% of OB/GYNs | NCBI/NIH data |
| Perimenopausal women who have discussed menopause with a healthcare provider | Only 49% of perimenopausal women | NCBI/NIH |
| Women who wait 6+ months with symptoms before seeking care | Approximately 50% | NCBI/NIH |
| US women who want more attention on menopause and women’s health | Significant majority (per Statista 2024 data) | Statista / NCBI/NIH |
| Women who feel comfortable discussing menopause at work | Only 31% | NCBI/NIH / Society for Women’s Health Research |
| Women who hide symptoms at work | 72% have hidden symptoms at work at least once | Society for Women’s Health Research / The World Data |
| Supervisors uncomfortable making menopause accommodations | 1 in 6 supervisors | NCBI/NIH, 2024–2025 data |
| US employers offering dedicated menopause benefits in 2026 | 25% — up from just 4% in 2023 | PwC, May 2026 |
| US women who benefit from knowing symptoms start earlier | 56% said earlier knowledge would have helped | Biote Survey, 2024 |
Source: National Library of Medicine (NCBI/NIH), Society for Women’s Health Research (SWHR), Biote Survey 2024, PwC Women’s Health Report May 2026
The perimenopause healthcare access crisis in the US in 2026 is rooted in a structural failure that begins in medical education itself. When only 31% of OB/GYN residency programs include any formal menopause curriculum, and an estimated ~80% of OB/GYNs report feeling undertrained in menopause management, it becomes almost inevitable that 49% of perimenopausal women have never had a meaningful menopause conversation with a healthcare provider — let alone received a diagnosis or treatment plan. Half of all symptomatic women wait 6 months or more before seeking care, often because they don’t recognize their symptoms as perimenopausal or fear not being taken seriously. This gap between symptom onset and clinical engagement is not a personal failing — it is a systemic one.
The workplace dimension compounds this healthcare gap dramatically. The fact that 72% of perimenopausal women have hidden their symptoms at work — and only 31% feel comfortable discussing them — reflects a broader cultural silence that delays care, accelerates career disengagement, and fuels the $26.6 billion annual economic loss documented by Mayo Clinic. The PwC 2026 report showing that 25% of US employers now offer dedicated menopause benefits — up from just 4% in 2023 — is a genuinely encouraging data point, but the critical caveat is that utilization remains low because employees simply don’t know these benefits exist. Education, not just access, is the missing link in 2026.
Perimenopause Racial & Ethnic Disparities in the US 2026
AVERAGE AGE AT MENOPAUSE BY RACE/ETHNICITY — US
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Non-Hispanic White Women ████████████████████ ~51 yrs (national median)
Black / African American ████████████████████ ~49 yrs (2 yrs earlier)
Hispanic / Latina Women ████████████████████ ~49 yrs (2 yrs earlier)
Japanese American Women █████████████████████ slightly later than median
Native Hawaiian Women ████████████████████ earlier than median
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Racial / Ethnic Group | Average Menopause Age | Key Disparity | Source |
|---|---|---|---|
| Non-Hispanic White Women | ~51 years (national median) | Baseline reference group | SWAN Study / SWHR |
| Black / African American Women | ~49 years — 2 years earlier | Longer transition period; more frequent + severe hot flashes (OR 1.87) | SWAN Study; Menopause Journal 2024 |
| Hispanic / Latina Women | ~49 years — 2 years earlier | Higher severity across multiple symptoms vs. White women (all p<0.01) | SWHR Fact Sheet; Menopause Journal 2024 |
| Japanese American Women | Slightly later than median | — | SWAN Study / SWHR |
| Native Hawaiian Women | Earlier than median | — | SWAN Study / SWHR |
| Black women’s MHT prescription rate | 26% less likely to be prescribed hormone therapy vs. White women | Documented in 200,000+ women VA study, 2022 | Healthline / Menopause Journal |
| Hispanic women’s MHT prescription rate | 32% less likely to be prescribed hormone therapy vs. White women | Same VA system study | Healthline / Menopause Journal |
| Black women — adverse work outcomes | Nearly 3x more likely to report adverse work outcomes due to symptoms | — | The World Data / Society for Women’s Health Research 2024–2025 |
| Indigenous/First Nations women | Most severe anxiety/depression (OR 1.70), painful sex (OR 1.77), joint pain (OR 1.73) | — | Menopause Journal, June 2024 (PubMed) |
Source: Study of Women’s Health Across the Nation (SWAN) — NIH-funded; Society for Women’s Health Research (SWHR) Menopause Disparities Fact Sheet; Menopause Journal June 2024 (PubMed); Bayer / Impacts of Menopause, July 2025
Perimenopause racial disparities in the US in 2026 represent one of the most troubling and under-addressed dimensions of women’s health inequality. Both Black and Hispanic women reach menopause approximately 2 years earlier than the national median, according to the long-running NIH-funded SWAN Study and confirmed by the Society for Women’s Health Research. This earlier onset carries real health consequences: longer lifetime exposure to the risks associated with low estrogen, including accelerated bone density loss and increased cardiovascular vulnerability. Yet despite experiencing more frequent and more severe symptoms — Black women, for instance, show an odds ratio of 1.87 for hot flashes compared to White women (Menopause Journal, 2024) — these same groups are less likely to receive treatment. A landmark study analyzing over 200,000 women in the US Veterans Health Administration found that Black women were 26% less likely and Hispanic women 32% less likely to be prescribed hormone therapy than White women with the same symptom profile.
This treatment gap is not a matter of preference alone. It reflects deeper systemic inequities in how symptoms are documented, how providers communicate with patients of color, and how research has historically centered White women’s experiences as the norm — a bias identified and partially quantified by Stanford and University of Michigan researchers in the SWAN selection bias analysis. The data for Indigenous/First Nations women is equally stark: this group shows the highest severity scores for anxiety, depression, painful sex, and joint/muscular discomfort among all racial groups studied (PubMed, June 2024). Addressing these disparities is not a secondary concern — it is central to any credible national strategy for perimenopause care in 2026 and beyond.
Perimenopause Economic Impact in the US 2026
ANNUAL ECONOMIC COST OF PERIMENOPAUSE / MENOPAUSE — US
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Lost work productivity (missed days) $1.8 Billion/yr ██████████
Direct medical costs (age 45-60) $24.8 Billion/yr ████████████████████
Total annual US economic cost $26.6 Billion/yr ████████████████████
Women's annual out-of-pocket spend $13 Billion/yr ██████████████████
- Non-medical treatments >$10 Billion/yr ████████████████████
- HRT costs ~$2.7 Billion/yr █████████████████
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Economic Metric | US Data | Source |
|---|---|---|
| Annual productivity loss from missed work | $1.8 billion/year | Mayo Clinic Study (cited by AARP, WEF, TIME) |
| Annual direct medical costs for women aged 45–60 | $24.8 billion/year | Mayo Clinic Study |
| Total annual US economic cost | $26.6 billion/year | Mayo Clinic (via TIME, February 2026) |
| Women who reported missing work in last 12 months due to symptoms | Nearly 11% of women aged 45–60 | Mayo Clinic survey of 4,400+ women |
| Women with at least one adverse work outcome | 13.4% of women aged 45–60 | Mayo Clinic / Impacts of Menopause, July 2025 |
| Women annually spending on treatments (total) | Over $13 billion | AARP Survey |
| Spending on non-medical treatments | Over $10 billion/year | AARP Survey |
| Spending on HRT | Approximately $2.7 billion/year | AARP Survey |
| Women who took time off work (aged 45–60) | 10% reported taking time off due to symptoms | WEF / WHO data 2024 |
| Earnings decline after menopause-related provider visit | 10% earnings decline over 4 years (Stanford research) | The World Data / Stanford University |
| US employers offering menopause benefits 2026 | 25% — up from 4% in 2023 | PwC Menopause Market Report, May 2026 |
| Projected postmenopausal women in US by 2060 | 90 million women | Bayer / Impacts of Menopause, July 2025 |
Source: Mayo Clinic workplace productivity study; AARP Survey on Menopause Spending; TIME Magazine February 2026; PwC Women’s Health Report May 2026; Stanford University research; Bayer / Impacts of Menopause July 2025
The economic cost of perimenopause in the US in 2026 is not an abstraction — it is a quantified, documented burden that the nation’s leading institutions have now placed firmly on the table. The Mayo Clinic’s comprehensive survey of over 4,400 US women aged 45–60 produced the landmark figure of $26.6 billion in annual losses — combining $1.8 billion in productivity losses from missed workdays alone and $24.8 billion in direct medical expenditures. This figure does not yet account for reduced work hours, early retirement, or career trajectory losses — meaning the true economic toll is considerably higher. Stanford research adds another painful data point: women who visit healthcare providers specifically for menopause-related symptoms see a 10% decline in earnings over the following four years, primarily because they shift to fewer hours or less demanding roles to cope with unmanaged symptoms.
Out of pocket, US women are spending over $13 billion annually managing their own perimenopause and menopause symptoms (AARP). More than $10 billion of that goes toward non-medical treatments — supplements, alternative therapies, lifestyle products — reflecting both the demand for relief and the gaps in formal clinical care. The encouraging trend from PwC’s May 2026 report — that employer menopause benefits have grown from 4% to 25% of US companies in just three years — signals that the business case for supporting perimenopausal employees is finally being recognized. But with utilization still low due to lack of employee awareness, and with the projected 90 million postmenopausal US women by 2060 on the horizon, the investment case for comprehensive perimenopausal health support has never been clearer or more urgent.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
